Injectable drug packaging failures can compromise patient safety, trigger regulatory action, and damage brand trust for years — making informed component selection a business-critical discipline. Datwyler's P.E.R.F.E.C.T. framework provides a structured, seven-step decision-making pathway for pharmaceutical professionals selecting elastomeric stoppers, plungers, and combiseals for vials, syringes, and cartridges.
The acronym covers:
-
Particulate (contamination sources, size categorization, and detection methods per USP <788>/<789>)
-
Extractables & Leachables (E&L migration risk, coating strategies, and patient population considerations)
-
Regulatory (global enforcement and standards mapping across FDA, EMA, NMPA, and other authorities)
-
Functionality (break-loose force, glide force, self-sealing, multipuncture, and plunger movement during transport)
-
Engineering Capabilities (fill/finish line compatibility, stickiness, twinning, bulging, and FAT/SAT testing)
-
Container Closure Integrity (interference fit evaluation, land and valve seal geometry, deterministic vs. probabilistic CCI test methods)
-
Total Quality (physical dimensions per ISO tolerances, chemical formulation consistency, and biological cleanliness including bioburden and endotoxin limits).
Drawing on Datwyler's proprietary quality data — including a survey showing cellulose accounts for 60.9% of particulate contamination in injectable products — the paper equips drug manufacturers with the knowledge to evaluate suppliers, reduce recall risk, and build regulatory-defensible packaging programs aligned with evolving FDA and EU GMP Annex 1 expectations.
